News

BelHealth Investment Partners, a healthcare-focused private equity firm, has acquired West Sacramento, California-based Gemini Bio-Products, a biological reagents manufacturer and supplier. No financial terms were disclosed.

PRESS RELEASE

New York, New York – September 14th, 2018 – BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, announced today that it has acquired Gemini Bio-Products, Inc. (“Gemini” or the “Company”), a leading biological reagents manufacturer and supplier serving the scientific community across academic research and the biotechnology and biopharma industries.

Founded in 1985 and headquartered in West Sacramento, California, Gemini is a supplier of cell culture media, sera, and other reagents to many of the top research and academic communities, biotechnology firms and pharmaceutical companies around the world. The Company has an established, reliable supply chain and sources the highest quality raw materials, which has translated into its exceptional products and a longstanding, pristine reputation. Gemini was founded by entrepreneur Bertram Polan.

BelHealth’s investment thesis is to create a diversified bio-products manufacturing platform. In order to drive continued organic growth, BelHealth will partner with experienced executives and utilize scientific talent to further build relationships with leading researchers in the biotechnology and academic communities to innovate through continued research and development. In addition, BelHealth is focused on expanding and enhancing Gemini’s manufacturing capabilities with higher quality and compliance standards. Furthermore, BelHealth will look to augment Gemini’s product portfolio through acquisitions of complementary biological reagents manufacturing companies.

Bert Polan, Founder of Gemini, said “I am proud at what our team at Gemini has been able to accomplish over the last 33 years. We are thrilled to partner with BelHealth for the next chapter of growth. We look forward to leveraging their experience and network to scale our established platform through facility and product portfolio expansions. Furthermore, we are excited for the investment capital that BelHealth will provide to fund these key growth initiatives.”

Harold S. Blue, Managing Partner of BelHealth added, “We developed a thesis to invest in supplying the burgeoning field of cell therapy and regenerative medicines. Gemini is the perfect investment for our thesis.

As the biotechnology field continues to evolve, these companies will require more quality biological reagents to create world-class therapies, and will look to rely on high quality, experienced vendors like Gemini. The Company has proven its high touch service and ability to make customized solutions, which positions it very well for robust growth.”

About Gemini Bio-Products
Founded in 1985, Gemini is a supplier of cell culture media, sera, and other reagents to many of the world’s top research and academic communities, biotechnology firms, and pharmaceutical companies. Today, Gemini operates from a 14,000 square foot manufacturing facility in West Sacramento, California. A national sales force and an international distribution network serves cell culture laboratories worldwide.

About BelHealth Investment Partners
BelHealth Investment Partners, based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes would benefit from its extensive operating and private equity investment expertise. The firm invests across three core healthcare segments: Services, Products and Distribution. BelHealth is investing from its current $350 million fund.

For further information, please visit: BelHealth Investment Partners: www.belhealth.com